NEUP
Neuphoria Therapeutics Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$3.31
+0.30%Year over year
Reported trailing growth
- Revenue
- -79.0%
- EBITDA
- —
- EBIT
- -46.1%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +85.0%
- EBITDA
- -64.9%
- EPS
- +45.5%
Three-year CAGR
- Revenue
- -92.5%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026